Cancer-Associated Thrombosis: Anticoagulation Strategies and Emerging Therapies

Review in Current Practice in Venous Thromboembolism is a two-day live virtual conference dedicated to advancing the understanding and management of VTE. Join leading experts as they explore emerging science, evolving risk stratification tools, and modern therapeutic strategies across diverse patient populations. This focused update on thrombosis care offers clinicians practical, evidence-based insights to improve outcomes across inpatient, outpatient, and high-risk settings.
Key Topics
Innovations in VTE: Advances in diagnostics, risk prediction, and the future of thrombosis care
Inpatient to Post-Discharge: Continuum of VTE prevention in hospitalized medical patients
Risk Stratification 2.0: Newer techniques using biomarkers & imaging advancements
Specialised care: including VTE management in women and the elderly
Procedural Interventions in DVT: What every physician should know about IVC filters and venous stents
Cancer-Associated Thrombosis: Personalized anticoagulation and new therapy frontiers
Managing APLA Syndrome: From diagnosis to long-term thrombosis prevention
This comprehensive review will help refine your clinical decision-making in VTE care. Stay updated, stay prepared-Register now to secure your spot.

RCP VTE Day 2

Accurate VTE risk assessment is critical, yet current tools have limitations in precision and accessibility. Under the chairmanship of Dr Abhay Bhave, with panelist Dr Velu Nair, this discussion will delve into the emerging role of biomarkers, advanced imaging modalities, and AI-driven models in transforming how clinicians predict and prevent VTE.

Revolutionizing VTE Risk Assessment: Biomarkers, Imaging, and AI Integration

RCP VTE Day 1

Experience a crucial live session with Dr. Abhay Bhave and Lt Gen (Dr) Velu Nair on optimizing anticoagulant therapy. This session will cover effective strategies for educating patients on adherence, managing side effects, and implementing lifestyle changes. Learn best practices for monitoring therapy, including assessing renal function and managing drug interactions. Discover the value of a multidisciplinary approach, collaborating with specialists like oncologists and nephrologists for comprehensive care. Evaluate real-world case studies to tackle practical challenges and engage in interactive discussions to apply theoretical knowledge to improve quality in anticoagulation therapy.

Anticoagulation Stewardship: Best Practices for Optimal Patient Care

Tune in for a pivotal live session with Lt Gen (Dr) Velu Nair and Dr. Tapish Sahu, focusing on optimizing anticoagulant therapy in special populations. This session will analyze case studies to compare the use of anticoagulants (LMWH/VKA vs. DOACs) among the elderly, obese individuals, and CKD patients. We’ll review insights from the CARAVAGGIO trial on DOACs for cancer-associated thrombosis, and explore the benefit-risk considerations for oncology patients. Additionally, we’ll examine thrombosis risk at high altitudes and strategies for managing anticoagulation in such conditions. Enhance your understanding of the efficacy and safety profiles of various anticoagulants and integrate these findings into clinical practice to improve patient outcomes.

VTE Management in Special Populations with a focus on Cancer - Associated Thrombosis and High Altitude Induced Thrombosis (The Plot behind the Clot)

Join Dr. Alexander Cohen and Lt Gen (Dr) Velu Nair for a crucial live session on Venous Thromboembolism (VTE). This session will cover VTE’s incidence, prevalence, and risk factors, with a focus on diagnostic delays and underdiagnosis in primary care. We will discuss VTE in special populations such as the elderly, obese, CKD patients, and those post-surgery or hospitalized. Learn about the pathophysiology of VTE, including clot formation and comorbid conditions, and compare conventional anticoagulants (VKAs/LMWH) with modern options (DOACs). Enhance your understanding and management of VTE.

Epidemiology and Pathophysiology of Venous Thromboembolism (VTE)

Join leading experts Dr. Alexander Cohen, Lt Gen (Dr) Velu Nair, Dr. Tulika Seth, and Dr. Abhay Bhave for a series of live sessions on Venous Thromboembolism (VTE). These sessions will delve into the incidence, prevalence, and risk factors of VTE, with a focus on diagnostic challenges and the impact on special populations. Explore the pathophysiology of VTE, compare traditional and modern anticoagulant therapies, and refine your risk assessment skills using key models like the Caprini, Wells, and Geneva Scores. Enhance your understanding and management of VTE to improve patient outcomes in clinical practice.

RCP - Venous Thromboembolism

Join Dr Mahadev Desai in the latest episode of Changing Practice: June Roundup as we explore June's groundbreaking medical advancements. From cancer research to cardiovascular innovations, stay informed on the latest trends. In this episode, we discuss the latest on fluid therapy for critically ill adults with sepsis, posterior reversible encephalopathy syndrome, megaloblastic anemia presenting as pyrexia & WHO's recent warning on sugar substitutes. Share this #MustAttendSession with colleagues and tune in to Medflix for a blockbuster discussion on medical progress!

Changing Practice: June Roundup!

Head & Chief Consultant – Haemato-Oncology & Bone Marrow Transplant, Apollo Cancer Center, Apollo Hospitals International Limited, Gandhinagar

The Review of Current Practices (RCP) on venous thromboembolism (VTE) kicks off with a focused and clinically rich Day 1, chaired by Lt Gen (Dr.) Velu Nair (Retd.). Designed for busy clinicians, the evening features 3 expert-led sessions that lay the foundation for evidence-based VTE management.

The agenda begins with an overview of contemporary approaches, followed by a discussion of thromboprophylaxis and risk stratification, emphasizing translation of evidence into real-world clinical decision-making. This is complemented by a session on catheter-related thrombosis, bringing in interventional and surgical perspectives.

The day culminates in an in-depth panel discussion, focusing on personalizing VTE management in complex “grey zone” populations, including obesity, bleeding risk, renal dysfunction, and young adults.

With interactive elements such as live polls, audience Q&A, and case-based insights, Day 1 sets the stage for a practical, nuanced understanding of VTE management. Participants will also engage through pre–post assessments, with certificates awarded upon completion.

RCP VTE 2026 - Day 1

An interactive panel discussion on personalizing VTE management in challenging patient populations. Led by Dr. Velu Nair, the session tackles clinical grey zones, including obesity, active bleeding risk, stroke prevention in atrial fibrillation (SPAF), renal failure, and VTE in young adults, providing nuanced, individualized approaches grounded in current evidence and real-world practice.

From Guidelines to Ground Reality: Personalizing VTE Management in the Grey Zone Population

Day 2 of the Review of Current Practices (RCP) on venous thromboembolism (VTE) builds on foundational concepts with a sharper focus on high-risk scenarios and evolving treatment paradigms. Chaired by Lt Gen (Dr.) Velu Nair (Retd.), the day features 4 expert-led sessions designed to refine clinical decision-making.

The evening begins with a recap of key Day 1 insights, followed by a keynote by Dr. Velu Nair on cancer-associated thrombosis, addressing treatment complexities in high-risk patients. Then presents emerging evidence in anticoagulation, with insights from the COBRRA trial and its clinical implications.

Subsequent sessions include rationalizing the use of DOACs, LMWH, and oral anticoagulants, and a discussion on selecting between interventional and medical management strategies in VTE.

The program concludes with closing remarks and key takeaways, reinforcing practical application. As with Day 1, the format remains highly interactive with live polls, audience engagement, and knowledge assessments, ensuring meaningful learning outcomes for participants.

RCP VTE 2026 - Day 2

Dr Velu Nair navigates the complex landscape of cancer-associated thrombosis (CAT), one of the most clinically challenging subsets of VTE. The session addresses risk stratification in oncology patients, the comparative efficacy and safety of DOACs versus LMWH, management in the context of thrombocytopenia and drug interactions, and practical decision frameworks for high-risk patients.

Cancer‑Associated Thrombosis: Navigating Treatment Decisions in High‑Risk Patients

This session will cover a critical and balanced appraisal of the major anticoagulant classes: DOACs, LMWH, and Vitamin K antagonists ; contextualizing their roles across VTE indications. The session focuses on practical prescribing considerations, patient-specific factors influencing drug choice, monitoring requirements, reversal strategies, and aligning therapy with guidelines and real-world clinical constraints.

Dr. Lt Gen Velu Nair

15

5.7k

273.9k

4.8

Upcoming Sessions

Sessions Taken

919

4.7

844

4.8

1.2k

4.7

1k

4.7

2.2k

0

2.2k

0

2.2k

0

2.2k

4.8

1.1k

4.8